For years, the treatment of ANCA-associated vasculitis (AAV) has largely revolved around controlling inflammation and preventing irreversible damage to vital organs, particularly the kidneys and lungs. But growing evidence is changing that clinical perspective. AAV—covering conditions such as granulomatosis with polyangiitis, microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis—is increasingly being associated with a substantially greater burden of cardiovascular disease.
Patients living with AAV may face an elevated risk of major cardiovascular events, including heart attacks, strokes and heart failure. Importantly, this danger does not necessarily disappear when the autoimmune disease enters remission. The findings suggest that systemic inflammation, vascular injury and treatment-related metabolic complications can continue to influence cardiovascular health long after the most obvious symptoms of vasculitis have subsided.
Inflammation and the Cardiovascular System
AAV develops when the immune system produces antibodies targeting proteins such as proteinase 3 and myeloperoxidase. These antibodies can activate neutrophils, triggering inflammation and damage to blood-vessel walls. Although the kidneys and lungs are among the organs most visibly affected, the inflammatory process is systemic.
Persistent inflammation can impair the endothelium—the delicate inner lining of blood vessels—and contribute to changes associated with atherosclerosis. Inflammatory mediators such as interleukin-6 and tumor necrosis factor-alpha may further promote vascular dysfunction and contribute to instability within existing arterial plaques.
This provides a biological explanation for why cardiovascular complications can emerge alongside, or even after, successful control of the primary vasculitis.
A Significant Cardiovascular Burden
Studies examining people with AAV have reported considerably higher cardiovascular-event rates than those observed in comparable populations without vasculitis. The danger appears particularly pronounced during the early period following diagnosis, when inflammatory activity may be at its greatest.
However, the elevated risk can persist during remission. Researchers believe that cumulative vascular injury, continuing low-level inflammation and conventional risk factors may combine to produce long-term cardiovascular consequences.
Heart attacks and ischemic strokes are among the major concerns, while heart failure and blood-clotting complications have also been reported more frequently in people with systemic inflammatory diseases.
The Steroid Challenge
Another important consideration is treatment. Glucocorticoids remain an important component of AAV therapy, particularly during severe disease. They can rapidly suppress potentially life-threatening inflammation, but prolonged exposure can contribute to high blood pressure, elevated blood glucose, weight gain and abnormal cholesterol levels.
These metabolic effects can themselves increase cardiovascular risk.
Consequently, modern AAV management increasingly emphasizes reducing unnecessary long-term steroid exposure whenever clinically appropriate. Steroid-sparing approaches, including therapies such as rituximab and avacopan in appropriate patients, have expanded the options available to clinicians. Nevertheless, cardiovascular monitoring remains essential throughout treatment.
Rethinking Patient Monitoring
The growing recognition of cardiovascular complications means that achieving remission should no longer be regarded as the only long-term treatment objective. Patients with AAV may benefit from systematic assessment of conventional cardiovascular risk factors alongside monitoring of autoimmune disease activity.
Blood pressure, cholesterol, blood glucose, smoking status, body weight and other established risk factors should be regularly evaluated. In selected patients, clinicians may also consider investigations for previously unrecognized vascular disease.
Standard cardiovascular risk calculators may not completely capture the additional burden created by chronic inflammatory disease. This highlights the need for better risk-assessment models specifically designed for people with systemic autoimmune conditions.
Toward a More Comprehensive Model of Care
The emerging evidence surrounding AAV and cardiovascular disease represents an important shift in clinical thinking. Vasculitis should not be viewed solely as a disorder affecting individual organs. Its inflammatory effects can extend throughout the vascular system, potentially creating cardiovascular consequences that persist beyond periods of active disease.
The future of AAV care therefore lies in a more integrated approach involving rheumatologists, nephrologists, cardiologists, primary-care physicians and other specialists. Controlling inflammation, minimizing cumulative steroid exposure and aggressively addressing conventional cardiovascular risk factors should become complementary elements of long-term management.
Ultimately, remission is only one part of the goal. Protecting the heart and blood vessels may be equally important in improving survival and quality of life for people living with ANCA-associated vasculitis. As understanding of the disease continues to evolve, cardiovascular protection should move from the margins of AAV management to a central component of comprehensive autoimmune care.
Leave a Reply